{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:35:38Z","timestamp":1740123338542,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s10637-019-00863-8","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T05:41:27Z","timestamp":1573796487000},"page":"866-873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy"],"prefix":"10.1007","volume":"38","author":[{"given":"Byeong Seok","family":"Sohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hee","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Hyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Jin","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hong","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5588-8332","authenticated-orcid":false,"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"863_CR1","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/jco.2010.28.5437","volume":"29","author":"W Eiermann","year":"2011","unstructured":"Eiermann W, Pienkowski T, Crown J et al (2011) Phase III study of doxorubicin\/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29:3877\u20133884. https:\/\/doi.org\/10.1200\/jco.2010.28.5437","journal-title":"J Clin Oncol"},{"key":"863_CR2","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/jco.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford JLyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167. https:\/\/doi.org\/10.1200\/jco.2006.08.8823","journal-title":"J Clin Oncol"},{"issue":"8 Pt 2","key":"863_CR3","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1592\/phco.23.9.3S.32886","volume":"23","author":"G Molineux","year":"2003","unstructured":"Molineux G (2003) Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23(8 Pt 2):3s\u20138s. https:\/\/doi.org\/10.1592\/phco.23.9.3S.32886","journal-title":"Pharmacotherapy"},{"issue":"4 Suppl 13","key":"863_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0093-7754(03)00314-2","volume":"30","author":"J Crawford","year":"2003","unstructured":"Crawford J (2003) Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 30(4 Suppl 13):24\u201330. https:\/\/doi.org\/10.1016\/S0093-7754(03)00314-2","journal-title":"Semin Oncol"},{"key":"863_CR5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/1381612043452613","volume":"10","author":"G Molineux","year":"2004","unstructured":"Molineux G (2004) The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 10:1235\u20131244. https:\/\/doi.org\/10.2174\/1381612043452613","journal-title":"Curr Pharm Des"},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/jco.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O'Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20:727\u2013731. https:\/\/doi.org\/10.1200\/jco.2002.20.3.727","journal-title":"J Clin Oncol"},{"key":"863_CR7","first-page":"715","volume":"10","author":"S Siena","year":"2003","unstructured":"Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett JRenwick JJ (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 10:715\u2013724","journal-title":"Oncol Rep"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29\u201335. https:\/\/doi.org\/10.1093\/annonc\/mdg019","journal-title":"Ann Oncol"},{"key":"863_CR9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1007\/s10637-013-9973-4","volume":"31","author":"KH Park","year":"2013","unstructured":"Park KH, Sohn JH, Lee S et al (2013) A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Investig New Drugs 31:1300\u20131306. https:\/\/doi.org\/10.1007\/s10637-013-9973-4","journal-title":"Investig New Drugs"},{"key":"863_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/annonc\/mdm438","volume":"19","author":"G von Minckwitz","year":"2008","unstructured":"von Minckwitz G, Kummel S, du Bois A et al (2008) Pegfilgrastim \u00b1 ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19:292\u2013298. https:\/\/doi.org\/10.1093\/annonc\/mdm438","journal-title":"Ann Oncol"},{"key":"863_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"D Weycker","year":"2006","unstructured":"Weycker D, Hackett J, Edelsberg JS, Oster GGlass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402\u2013407. https:\/\/doi.org\/10.1345\/aph.1G516","journal-title":"Ann Pharmacother"},{"issue":"2 Suppl","key":"863_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.18553\/jmcp.2003.9.s2.15","volume":"9","author":"SD Scott","year":"2003","unstructured":"Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman MStolshek BS (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm 9(2 Suppl):15\u201321. https:\/\/doi.org\/10.18553\/jmcp.2003.9.s2.15","journal-title":"J Manag Care Pharm"},{"key":"863_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000011926","volume":"56","author":"G Koumakis","year":"1999","unstructured":"Koumakis G, Vassilomanolakis M, Barbounis V, Hatzichristou E, Demiri S, Plataniotis G, Pamouktsoglou FEfremidis AP (1999) Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 56:28\u201335. https:\/\/doi.org\/10.1159\/000011926","journal-title":"Oncology"},{"key":"863_CR14","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/annonc\/mdl135","volume":"17","author":"M Martin","year":"2006","unstructured":"Martin M, Lluch A, Segui MA et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205\u20131212. https:\/\/doi.org\/10.1093\/annonc\/mdl135","journal-title":"Ann Oncol"},{"key":"863_CR15","doi-asserted-by":"publisher","first-page":"6908","DOI":"10.1200\/jco.2005.03.099","volume":"23","author":"P Papaldo","year":"2005","unstructured":"Papaldo P, Lopez M, Marolla P et al (2005) Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 23:6908\u20136918. https:\/\/doi.org\/10.1200\/jco.2005.03.099","journal-title":"J Clin Oncol"},{"key":"863_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","volume":"13","author":"VA Morrison","year":"2007","unstructured":"Morrison VA, Wong M, Hershman D, Campos LT, Ding BMalin J (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13:337\u2013348. https:\/\/doi.org\/10.18553\/jmcp.2007.13.4.337","journal-title":"J Manag Care Pharm"},{"key":"863_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1634\/theoncologist.12-4-484","volume":"12","author":"H Ozer","year":"2007","unstructured":"Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding BDreiling L (2007) Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 12:484\u2013494. https:\/\/doi.org\/10.1634\/theoncologist.12-4-484","journal-title":"Oncologist"},{"key":"863_CR18","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/jco.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212. https:\/\/doi.org\/10.1200\/jco.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"863_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"key":"863_CR20","unstructured":"National Comprehensive Cancer Network. (2019) Hematopoietic growth factors: NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) version 2.2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf. Accessed 21 August 2019"},{"key":"863_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","volume":"330","author":"G Bonadonna","year":"2005","unstructured":"Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni LValagussa P (2005) 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. Bmj 330:217. https:\/\/doi.org\/10.1136\/bmj.38314.622095.8F","journal-title":"Bmj"},{"issue":"5 Suppl 4","key":"863_CR22","first-page":"16","volume":"20","author":"M Rader","year":"2006","unstructured":"Rader M (2006) Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits. Oncology (Williston Park) 20(5 Suppl 4):16\u201321","journal-title":"Oncology (Williston Park)"},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/jco.2001.19.2.314","volume":"19","author":"JM Nabholtz","year":"2001","unstructured":"Nabholtz JM, Mackey JR, Smylie M et al (2001) Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 19:314\u2013321. https:\/\/doi.org\/10.1200\/jco.2001.19.2.314","journal-title":"J Clin Oncol"},{"key":"863_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3816\/CBC.2002.n.036","volume":"3","author":"RE Smith","year":"2002","unstructured":"Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP (2002) Phase II trial of doxorubicin\/docetaxel\/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clin Breast Cancer 3:333\u2013340. https:\/\/doi.org\/10.3816\/CBC.2002.n.036","journal-title":"Clin Breast Cancer"},{"key":"863_CR25","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302\u20132313. https:\/\/doi.org\/10.1056\/NEJMoa043681","journal-title":"N Engl J Med"},{"key":"863_CR26","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, Jones SE, O'Shaughnessy J et al (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903\u2013909. https:\/\/doi.org\/10.1093\/annonc\/mdf130","journal-title":"Ann Oncol"},{"issue":"16 suppl","key":"863_CR27","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1200\/jco.2005.23.16_suppl.6113","volume":"23","author":"LA Meza","year":"2005","unstructured":"Meza LA, Charu V, Campos L, Davis DXie F (2005) Pegfilgrastim and filgrastim patterns of use in community oncology practices: results of the ACCEPT study. J Clin Oncol 23(16 suppl):6113\u20136113. https:\/\/doi.org\/10.1200\/jco.2005.23.16_suppl.6113","journal-title":"J Clin Oncol"},{"key":"863_CR28","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1200\/jco.2005.05.078","volume":"23","author":"G von Minckwitz","year":"2005","unstructured":"von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German breast group. J Clin Oncol 23:2676\u20132685. https:\/\/doi.org\/10.1200\/jco.2005.05.078","journal-title":"J Clin Oncol"},{"key":"863_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3816\/CBC.2002.n.030","volume":"3","author":"JM Nabholtz","year":"2002","unstructured":"Nabholtz JM, Cantin J, Chang J et al (2002) Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel\/doxorubicin\/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 3:268\u2013275. https:\/\/doi.org\/10.3816\/CBC.2002.n.030","journal-title":"Clin Breast Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00863-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00863-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00863-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:38:29Z","timestamp":1678509509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00863-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00863-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"12 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that there exist no conflicts of interest in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}